| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.[1][2]
A study in non-human primates published in 2022 concluded S-268109-b demonstrated efficacy in a SARS-CoV-2 challenge experiment, although neutralizing antibodies against the Omicron variant were reduced.[3]
In a phase 1/2 clinical trial in Japan, the developers concluded reactions to the vaccine were mild, and neutralizing antibodies were similar to those in people who had recovered from Covid-19.[4] A phase 3 trial planned for 54,915 participants began in December 2021 in Vietnam.[5]
Preliminary results of a phase 2/3 trial using S-268019-b as a booster dose after two doses of the BNT162b2 vaccine by Pfizer concluded the vaccine was non-inferior to a booster dose of BNT162b2.[6]
- ^ "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 21 March 2021.
- ^ "A Phase 2/3 Study of S-268019". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 20 October 2021.
- ^ Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, et al. (July 2022). "Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys". Vaccine. 40 (31): 4231–4241. doi:10.1016/j.vaccine.2022.05.081. PMC 9167832. PMID 35691872.
- ^ Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, et al. (June 2022). "Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings". Vaccine. 40 (27): 3721–3726. doi:10.1016/j.vaccine.2022.04.054. PMC 9122779. PMID 35606235.
- ^ "A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Cross-over Study to Evaluate the Efficacy, Safety, and Immunogenicity of S-268019 for the Prevention of COVID-19". ClinicalTrials.gov. National Institutes of Health. 26 July 2022. Retrieved 19 September 2022.
- ^ Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, et al. (July 2022). "Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study". Vaccine. 40 (32): 4328–4333. doi:10.1016/j.vaccine.2022.06.032. PMC 9212435. PMID 35738968.